Tuesday, July 22, 2014

FDA Abroad - Pharmaceutical Executive

Read the full article: FDA Abroad - Pharmaceutical Executive:

"In India, America's second largest global source of API and finished drug products, some 1,965 manufacturing facilities export to the US, but only around 600 sites are registered with CDER, said Atul Agrawal, supervisory consumer safety officer at FDA's India office. Drug manufacturing capability in India doubled to represent 12% of total US drug imports in 2012, up from 6% in 2008. "India is a major player in the prescription drugs Americans take on a daily basis," said Agrawal, much to the envy of Chinese nationals everywhere. And yet, FDA's operation in India currently consists of five full-time Americans, and two locally employed staffers, spread across two offices, one in New Delhi and one in Mumbai."

'via Blog this'

Return to SkillsPlus International Info Blog - Home

SkillsPlus Intl Inc. - The Best GMP & QSR Compliance Training Around
New! cGMP Mini-Series - Multimedia clips to use in your GMP training

The cGMP Trainer Professionals Resources Blog
Sign-up for SkillsPlus Intl Inc Announcements via Constant Contact

Wednesday, July 16, 2014

U.S. Seeks Legislation to Curb Offshore Tax Deals - Bloomberg

Read the full article: U.S. Seeks Legislation to Curb Offshore Tax Deals - Bloomberg:

"In a letter calling for a “new sense of economic patriotism,” Treasury Secretary Jacob J. Lew said Congress should approve tax changes retroactive to May.

“We should prevent companies from effectively renouncing their citizenship to get out of paying taxes,” Lew wrote in the letter to top congressional tax writers, which was dated yesterday and obtained by Bloomberg News. “We should not be providing support for corporations that seek to shift their profits overseas to avoid paying their fair share of taxes.”

The mergers used to legally avoid taxes, known as inversion transactions, have become increasingly popular over the past year, particularly in the pharmaceutical industry. "

'via Blog this'

Return to SkillsPlus International Info Blog - Home

SkillsPlus Intl Inc. - The Best GMP & QSR Compliance Training Around
New! cGMP Mini-Series - Multimedia clips to use in your GMP training

The cGMP Trainer Professionals Resources Blog
Sign-up for SkillsPlus Intl Inc Announcements via Constant Contact

Tuesday, July 15, 2014

FDA Gives Guidance On Compounding For Human Use - mondaq

Read the full article: FDA Gives Guidance On Compounding For Human Use - Food, Drugs, Healthcare, Life Sciences - United States - mondaq:

"In July 2014, the U.S. Food and Drug Administration (FDA) released five documents containing policies and proposals that affect both traditional compounding pharmacies and outsourcing facilities that compound drugs for human use. These documents are:
  • Draft Interim Guidance setting forth FDA's current thinking as to its interim expectations for outsourcing facilities regarding compliance with Current Good Manufacturing Practices (CGMP) until regulations are developed; 
  • A Proposed Rule adding 25 new drug products to the "do-not-compound" list, for both traditional compounders and outsourcing facilities; 
  • Final Guidance for traditional compounders; and 
  • Two separate requests, one for 503A and one for 503B, to nominate bulk drug substances for FDA lists of active bulk substances that traditional compounders and outsourcing facilities are permitted to use."
'via Blog this'

Return to SkillsPlus International Info Blog - Home

SkillsPlus Intl Inc. - The Best GMP & QSR Compliance Training Around
New! cGMP Mini-Series - Multimedia clips to use in your GMP training

The cGMP Trainer Professionals Resources Blog
Sign-up for SkillsPlus Intl Inc Announcements via Constant Contact